0.260
-0.010
(-3.70%)
May 17 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.25 - 0.26 |
| 52 week | 0.23 - 1.90 |
| Open | 0.26 |
| Vol / Avg. | 60,841.00/35,845.00 |
| Mkt cap | 15.86M |
| P/E | - |
| Div/yield | - |
| EPS | -0.07 |
| Shares | 61.01M |
| Beta | 1.53 |
| Inst. own | - |
Events
Apr 11, 2013
Q1 2013 Thera Technologies Earnings Conference Call
Feb 27, 2013
Q4 2012 Thera Technologies Earnings Conference Call
|
|
Key stats and ratios
| Q1 (Feb '13) | 2012 | |
| Net profit margin | 103.39% | -102.75% |
| Operating margin | 96.72% | -109.43% |
| EBITD margin | - | -50.36% |
| Return on average assets | 21.41% | -31.25% |
| Return on average equity | 31.60% | -47.24% |
| Employees | 19 | - |
| Carbon Disclosure Rating | - | - |
Address
2310 boul Alfred-Nobel
MONTREAL, QC H4S2B4
Canada
+1-514-3367800 (Phone)
+1-514-3367242 (Fax)
MONTREAL, QC H4S2B4
Canada
+1-514-3367800 (Phone)
+1-514-3367242 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Theratechnologies Inc. is a specialty pharmaceutical company. The Company is engaged in the discovery and development of therapeutic peptide products, with focus on growth-hormone releasing factor (GRF) peptides. The Company�s product, EGRIFTA (tesamorelin for injection), is the therapy for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. As of November 30, 2011, the Company was marketed in the United States by EMD Serono, Inc. (EMD Serono). On January 10, 2011, EMD Serono launched EGRIFTA.
Officers and directors
| Paul Pommier | Independent Chairman of the Board | |
| Luc Tanguay | Interim President, Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President, Director | |
| Marie-Noel Colussi | Vice President - Finance | |
| Jocelyn Lafond | Vice President - Legal Affairs, Corporate Secretary | |
| Christian Marsolais Ph.D. | Vice President - Scientific Affairs and Alliances | |
| Pierre Perazzelli | Vice President - Pharmaceutical Development | |
| Krishna Peri Ph.D. | Vice President - Research | |
| Dawn Graham | Director | |
| Gilles Cloutier Ph.D. | Independent Director | |
| Gerald A. Lacoste QC | Independent Director |
